Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world.
Researchers from PhRMA member companies work every day to research and develop game-changing science into new treatments and cures. Notably the last few years has brought about a sea change of innovation from biopharmaceutical R&D including but not limited to:
- More than 1,500 clinical trials testing over 500 unique therapies & more than 30 vaccines for COVID-19.
- Curing more than 90% of patients with hepatitis C, avoiding cases of liver failure and transplants.
- Changing how we diagnose and treat many patients with the advancement of personalized medicine.
- Transforming HIV/AIDS into a chronic and manageable disease, with an 88% decline in death rates in the United States.
- Harnessing the immune system to fight cancer in completely new ways. The cancer death rate peaking at its highs in the 1990’s has declined 29% thanks in part to innovative medicines.
Today, biopharmaceutical researchers from PhRMA member companies will be virtually connecting with Capitol Hill to discuss this highly complex and often risky work which must be protected to ensure the next set of breakthroughs for patients can come to fruition. The biopharmaceutical sector depends on strong intellectual property protections, efficient regulatory systems and a competitive marketplace to deliver innovative medicines and improve the lives of patients in unprecedented ways.
The current U.S. policy framework supports a unique interdependent research community that encourages public-private collaboration and incentivizes investment. This American innovation ecosystem must be preserved, especially as researchers work tirelessly to develop ways to diagnose, prevent and treat COVID-19.
We look forward to having meaningful conversations with members of Congress to discuss the highly successful U.S. biopharmaceutical research ecosystem and ensure it can continue to yield breakthrough advancements for patients. Learn more about America’s innovative biopharmaceutical ecosystem here.
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.